Angiopoietin-1 Modified Human Umbilical Cord Mesenchymal Stem Cell Therapy for Endotoxin- Induced Acute Lung Injury in Rats
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Angiopoietin-1 (Ang1) is a critical factor for vascular stabilization and endothelial survival via inhibition of endothelial permeability and leukocyte- endothelium interactions. Hence, we hypothesized that treatment with umbilical cord mesenchymalstem cells (UCMSCs) carrying the Ang1 gene (UCMSCs-Ang1) might be a potential approach for acute lung injury (ALI) inducedby lipopolysaccharide (LPS). Materials and Methods: UCMSCs with or without transfection with the human Ang1 gene were delivered intravenously into rats one hour after intra-abdominal instillation of LPS to induce ALI. After the rats were sacrificed at 6 hours, 24 hours, 48 hours, 8 days, and 15 days post-injection of LPS, the serum, the lung tissues, and bronchoalveolar lavage fluid (BALF) were harvested for analysis, respectively. Results: Administration of fluorescence microscope confirmed the increased presence of UCMSCs in the injured lungs. The evaluationof UCMSCs and UCMSCs-Ang1 actions revealed that Ang1 overexpression further decreased the levels of the pro-inflammatorycytokines TNF-α, TGF-β1, and IL-6 and increased the expression of the anti-inflammatory cytokine IL-10 in the injured lungs. This synergy caused a substantial decrease in lung airspace inflammation and vascular leakage, characterized by significantreductions in wet/dry ratio, differential neutrophil counts, myeloperoxidase activity, and BALF. The rats treated by UCMSCs-Ang1 showed improved survival and lower ALI scores. Conclusion: UCMSCs-Ang1 could improve both systemic inflammation and alveolar permeability in ALI. UC-derived MSCs-based Ang1 gene therapy may be developed as a potential novel strategy for the treatment of ALI.
Abstract
Purpose: Angiopoietin-1 (Ang1) is a critical factor for vascular stabilization and endothelial survival via inhibition of endothelial permeability and leukocyte- endothelium interactions. Hence, we hypothesized that treatment with umbilical cord mesenchymalstem cells (UCMSCs) carrying the Ang1 gene (UCMSCs-Ang1) might be a potential approach for acute lung injury (ALI) inducedby lipopolysaccharide (LPS). Materials and Methods: UCMSCs with or without transfection with the human Ang1 gene were delivered intravenously into rats one hour after intra-abdominal instillation of LPS to induce ALI. After the rats were sacrificed at 6 hours, 24 hours, 48 hours, 8 days, and 15 days post-injection of LPS, the serum, the lung tissues, and bronchoalveolar lavage fluid (BALF) were harvested for analysis, respectively. Results: Administration of fluorescence microscope confirmed the increased presence of UCMSCs in the injured lungs. The evaluationof UCMSCs and UCMSCs-Ang1 actions revealed that Ang1 overexpression further decreased the levels of the pro-inflammatorycytokines TNF-α, TGF-β1, and IL-6 and increased the expression of the anti-inflammatory cytokine IL-10 in the injured lungs. This synergy caused a substantial decrease in lung airspace inflammation and vascular leakage, characterized by significantreductions in wet/dry ratio, differential neutrophil counts, myeloperoxidase activity, and BALF. The rats treated by UCMSCs-Ang1 showed improved survival and lower ALI scores. Conclusion: UCMSCs-Ang1 could improve both systemic inflammation and alveolar permeability in ALI. UC-derived MSCs-based Ang1 gene therapy may be developed as a potential novel strategy for the treatment of ALI.
참고문헌 (20)
- Mei SH, "Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1", PLoS Med, 4, pp.e269~ (2007)
- Gotts JE, "Mesenchymal stem cells and acute lung injury", Crit Care Clin, 27, pp.719~733 (2011)
- Gharib SA, "Computational identification of key biological modules and transcription factors in acute lung injury", Am J Respir Crit Care Med, 173, pp.653~658 (2006)
- Slutsky AS, "PEEP or no PEEP--lung recruitment may be the solution", N Engl J Med, 354, pp.1839~1841 (2006)
- Harting MT, "Intravenous mesenchymal stem cell therapy for traumatic brain injury", J Neurosurg, 110, pp.1189~1197 (2009)
- Li J, "Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPSinduced acute lung injury in rats", J Inflamm (Lond), 9, pp.33~ (2012)
- Paul A, "Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction", Int J Nanomedicine, 7, pp.663~682 (2012)
- Xu J, "Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice", J Pathol, 214, pp.472~481 (2008)
- Gupta N, "Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice", J Immunol, 179, pp.1855~1863 (2007)
- Davies MJ, "Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention", J Clin Biochem Nutr, 48, pp.8~19 (2011)
- Bustos ML, "Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response", Am J Respir Crit Care Med, 189, pp.787~798 (2014)
- Fang X, "Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1", J Biol Chem, 285, pp.26211~26222 (2010)
- Kanki-Horimoto S, "Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension", Circulation, 114(1 Suppl), pp.I181~I185 (2006)
- Yamada M, "Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury", J Immunol, 172, pp.1266~1272 (2004)
- Thurston G, "The anti-inflammatory actions of angiopoietin-1", EXS, (94), pp.233~245 (2005)
- Gamble JR, "Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions", Circ Res, 87, pp.603~607 (2000)
- Piao W, "Transplantation of Sendai viral angiopoietin-1-modified mesenchymal stem cells for ischemic limb disease", Angiogenesis, 13, pp.203~210 (2010)
- McCarter SD, "Cell-based angiopoietin-1 gene therapy for acute lung injury", Am J Respir Crit Care Med, 175, pp.1014~1026 (2007)
- Bhandari V, "Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death", Nat Med, 12, pp.1286~1293 (2006)
- Johnson ER, "Acute lung injury: epidemiology, pathogenesis, and treatment", J Aerosol Med Pulm Drug Deliv, 23, pp.243~252 (2010)